Cornerstone's Strategic Transaction with Chiesi
Taskin Ahmed
Abstract
Cornerstone gains an exclusive 10 year license for US commercial rights to the marketed respiratory drug, Curosurf, and receives cash proceeds of US$15.5 M.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.